Skip to main content
Premium Trial:

Request an Annual Quote

Med Fusion HemeSEQ Profiles

Med Fusion has launched an expansion of its oncology testing services to include HemeSEQ portfolio of next-generation sequencing profiles. The profiles cover four hematologic neoplasms: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, and Myeloproliferative Neoplasms. These profiles expand the company's hematologic testing menu to nearly 100 tests and incorporate next-generation sequencing technology. Customer tests results are matched with relevant clinical trials and therapy options based on the specific genomic signature of the patient's disease, the company said. The final report is easy to read and delivers oncologists a powerful tool to access diagnosis and prognosis of patients living with hematologic disease.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.